Systemic Administration of a Novel Immune-Stimulatory Pseudovirion Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN-γ Production

@article{Saga2012SystemicAO,
  title={Systemic Administration of a Novel Immune-Stimulatory Pseudovirion Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN-$\gamma$ Production},
  author={Kotaro Saga and Katsuto Tamai and Takehiko Yamazaki and Yasufumi Kaneda},
  journal={Clinical Cancer Research},
  year={2012},
  volume={19},
  pages={668 - 679}
}
Purpose: Cancer immunotherapy has encountered many difficulties in the face of the expectation to eradicate cancer, and new breakthroughs are required. We have previously shown that UV-inactivated Sendai virus particles (hemagglutinating virus of Japan envelope; HVJ-E) induce immunity against multiple tumor types. In this study, a novel pseudovirion that stimulates more robust antitumor immunity was designed for cancer treatment. Experimental Design: First, we found that culturing murine… 
Cancer immunotherapy using the Fusion gene of Sendai virus
TLDR
It is found that F plasmid treatment resulted in a significant increase in the secretion of the chemokine RANTES by tumour-infiltrating T cells, which means F gene therapy may show promise as a novel therapeutic for single or combined cancer immunotherapy.
CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy
TLDR
It is demonstrated that the anti-tumor activities of C/H treatment were enhanced by the administration of anti-PD-1 antibodies through neutrophil-mediated cytotoxic T lymphocyte activation, which indicates the role of N1-type neutrophils in cancer immunotherapy.
Fusogenic Viruses in Oncolytic Immunotherapy
TLDR
The potential of fusogenic oncolytic viruses as optimal candidates to enhance immunotherapy and initiate broad antitumor responses is discussed, and growing evidence indicates that fusogenicity could be an important feature to consider in the design of optimal onColytic virus platforms for combinatorial on colytic immunotherapy.
Oncolysis by paramyxoviruses: preclinical and clinical studies
TLDR
In general, preclinical studies and phase 1–3 clinical trials yield very encouraging results and warrant continued research of oncolytic paramyxoviruses as a particularly valuable addition to the existing panel of cancer-fighting approaches.
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency
Oncolytic paramyxoviruses include some strains of Measles, Mumps, Newcastle disease, and Sendai viruses. All these viruses are well equipped for promoting highly specific and efficient malignant cell
Combination therapy with α-galactosylceramide and a Toll-like receptor agonist exerts an augmented suppressive effect on lung tumor metastasis in a mouse model.
TLDR
GalCer and LPS combination therapy significantly enhanced tumor antigen-specific immune responses and suppressed tumor growth in a mouse lung-metastasis model.
Inactivated Sendai virus induces apoptosis mediated by reactive oxygen species in murine melanoma cells.
TLDR
It is suggested that HVJ-E possesses potential anticancer activity in B16F10 cells through ROS-mediated mitochondrial dysfunction involving the MAPK pathway.
Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy
TLDR
The advances made in development of NK cell therapeutics for clinical application are highlighted with evidence supporting their combinatorial application with other immune-oncology approaches to improve outcomes of immunotherapies.
Change in Oncolytic Activity of Sendai Virus during Adaptation to Cell Cultures
TLDR
The stability of the Sendai virus genome is important for the implementation of its oncolytic potential, and this must be taken into account when choosing a technique for the production of antitumor drugs based on this virus.
Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood.
TLDR
CB-CIK cells exhibit more efficient anti-tumor activity in in vitro analysis and in the preclinical model and may serve as a potential therapeutic approach for the treatment of cancer.
...
1
2
...

References

SHOWING 1-10 OF 66 REFERENCES
Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells.
TLDR
This is the first report to show that HVJ-E alone can eradicate tumors and the mechanism through which it induces antitumor immune responses and shows promise as a novel therapeutic for cancer immunotherapy.
Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation
TLDR
It is reported that inactivated, replication-defective Sendai virus particles (HVJ-E) also has an antitumor effect through non-T cell immunity, and injection caused systemic activation of NK cells and enhanced their cytotoxity against tumor cells.
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.
TLDR
IL-12 is an effective and minimally toxic antitumor agent in murine tumor models and leads to an immune-mediated rejection involving, at least in part, IFN-gamma, CD4+, and CD8+ cells.
Next generation of immunotherapy for melanoma.
  • J. Kirkwood, A. Tarhini, +4 authors H. Gogas
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
The successes of cytokine and interferon therapy of melan cancer, coupled with an array of new approaches, are generating new enthusiasm for the immunotherapy of melanoma.
Antitumor and antimetastatic activity of interleukin 12 against murine tumors
TLDR
It is demonstrated that IL-12 has potent in vivo antitumor and antimetastatic effects against murine tumors and as well the critical role of CD8+ T cells in mediating the antitumors effects against subcutaneous tumors.
Interleukin-12 in anti-tumor immunity and immunotherapy.
TLDR
Excessive clinical toxicity and modest clinical response observed in the clinical trials point to the necessity to plan protocols that minimize toxicity without affecting the anti-tumor effect of IL-12.
Interferon-γ and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma
TLDR
Rec recombinant human IL-12 therapy of patients with RCC has the potential to induce the expression of gene products within the tumor bed that may contribute to the development of a successful antitumor response.
Interferon-g and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma 1
Interleukin 12 (IL-12) is known to play an important role in the development of an antitumor response. Its activity has been shown to be dependent upon the intermediate production of IFN-g and the
Development of a transferrin receptor-targeting HVJ-E vector.
TLDR
An HVJ (hemagglutinating virus of Japan) envelope (HVJ-E) vector using inactivated Sendai virus is developed, and modified vectors containing Q-dots demonstrated 32-fold greater tumor-targeting efficiency than wild-type HVj-E.
A Role of Interferon-γ (IFN-γ) in Tumor Immunity: T Cells with the Capacity to Reject Tumor Cells Are Generated But Fail to Migrate to Tumor Sitesin IFN-γ-deficient Mice
TLDR
A critical requirement for IFN-γ is indicated in the process of inducing T-cell migration to tumor sites rather than of generating antitumor protective T cells.
...
1
2
3
4
5
...